Scarica l'app Stockscreener
4.78
4.14%
0.19
Dopo l'orario di chiusura:
4.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$4.59
Aprire:
$4.5
Volume 24 ore:
5.59M
Relative Volume:
2.22
Capitalizzazione di mercato:
$365.84M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-1.8456
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+16.02%
1M Prestazione:
-13.87%
6M Prestazione:
-13.87%
1 anno Prestazione:
-28.01%
Intervallo 1D:
$4.37
$5.50
Intervallo di 1 settimana:
$4.27
$5.81
Portata 52W:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta VERV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
4.78 | 365.84M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-10-06 | Iniziato | Credit Suisse | Neutral |
| 2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-07-12 | Iniziato | Guggenheim | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Neutral |
| 2021-07-12 | Iniziato | Jefferies | Buy |
| 2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN
Verve impresses investors with second shot at PCSK9 - biocentury.com
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - marketscreener.com
Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail
Guggenheim raises Verve Therapeutics stock target to $24 By Investing.com - Investing.com Canada
Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - marketscreener.com
Guggenheim Boosts Price Target for Verve Therapeutics (VERV) to $24 | VERV Stock News - GuruFocus
Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results - insights.citeline.com
Early stage cardio data from Verve bump the stock - BioWorld MedTech
Assessing Verve Therapeutics: Insights From 4 Financial Analysts - Benzinga
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Yahoo Finance
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. - Barron's
Verve shares soar after new gene-editing trial shows no safety concerns - The Boston Globe
Verve Therapeutics: FDA Nod Sparks Stock Surge - timothysykes.com
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment? - RagingBull
Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive
Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns - Bloomberg.com
Verve Therapeutics Stock Rise: Is It A Turning Point? - timothysykes.com
Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial - MarketScreener
Verve Therapeutics reports promising trial results for cholesterol drug By Investing.com - Investing.com Canada
Verve Therapeutics reports promising trial results for cholesterol drug - Investing.com Australia
Verve Therapeutics stock soars on positive clinical trial results By Investing.com - Investing.com Nigeria
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - Yahoo
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - ACCESS Newswire
Verve stock gains on FDA fast track tag (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status - Stock Titan
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Strengthens Team with Strategic Equity Awards Worth $232K - Stock Titan
Verve Therapeutics CEO Sekar sells $40,761 in stock By Investing.com - Investing.com India
Verve therapeutics CAO Joan Nickerson sells $11,524 in stock - Investing.com India
Verve Therapeutics CEO Sekar sells $40,761 in stock - Investing.com
Verve Therapeutics Executives Sell Shares - TradingView
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):